PURE Bioscience, Inc.
PURE · OTC
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Market Cap | – | $10 | $7 | $8 |
| - Cash | $1 | $0 | $1 | $0 |
| + Debt | $4 | $5 | $5 | $4 |
| Enterprise Value | – | $15 | $11 | $12 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | -7.3% | 55.6% | 25.6% | – |
| Gross Profit | $0 | $1,302 | $0 | $0 |
| % Margin | 63.6% | 170,440.4% | 57.6% | 58.1% |
| EBITDA | -$0 | -$0 | -$1 | -$1 |
| % Margin | -52.1% | -31.8% | -102% | -185.9% |
| Net Income | -$0 | -$0 | -$1 | -$1 |
| % Margin | -65.5% | -43.5% | -118.1% | -204.1% |
| EPS Diluted | -0.004 | -0.003 | -0.005 | -0.007 |
| % Growth | -36.7% | 42.3% | 26.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$1 | -$1 |